The study showed that patients on Wegovy were about 15 percent less likely to die from cardiovascular disease and 23 percent less likely from other reasons as compared to those who took a placebo.
The fact that semaglutide reduced non-cardiovascular death, and in particular COVID-19-related deaths, was surprising. It opens up new avenues for exploring how this class of drugs may benefit patients.
The trial started before COVID-19, and we never anticipated a global respiratory pandemic. It is rare for a cardio-metabolic drug to modify non-cardiovascular outcomes.
The researchers do not know if the benefit of Wegovy is due to weight loss or other effects, but suggest that extra weight may be the greatest contributor to lower life expectancy.
Collection
[
|
...
]